Engaging Participants in Rare Disease Research: A Qualitative Study of Duchenne Muscular Dystrophy
Introduction
A global issue and a serious concern for most research studies in rare diseases is the successful and rapid recruitment of study participants.1 Our ability to achieve and measure progress in clinical trials in rare diseases is severely constrained by recruitment difficulties and low levels of patient and family participation.2, 3, 4, 5, 6 Successful completion of clinical trials fully depends on efficacious engagement with the intended beneficiaries. Clinical trials that do not have full inclusion of patients may affect how well new therapies perform in clinical practice. Specifically, substantial barriers exist to recruiting and conducting clinical trials in pediatric patients with rare neuromuscular diseases, such as Duchenne muscular dystrophy (DMD). DMD is the most common form of muscular dystrophy and affects 1 in 3500 to 6000 males in the United States.7, 8, 9, 10, 11
In the United States alone, there are currently >20 active clinical trials in DMD requiring >2300 boys with DMD to enroll.12 These figures may not include many investigator-initiated observational studies, sample collections, or quality-of-life surveys. Among the current studies that have met enrollment numbers, the inclusion of minority groups is also significantly low.13, 14 A representative population sample in clinical trials is essential both from an ethical perspective and for external validity of findings.15, 16, 17
There are a multitude of challenges regarding recruiting and engaging participants in research in DMD. Significant challenges include the heterogeneity of the condition, the small number of individuals with DMD, and the limited clinical sites with the expertise in recruiting for and performing clinical studies in DMD.4, 14 Moreover, many interventions in DMD are targeted to specific mutations (nonsense mutations or mutations that are amenable to certain exon-skipping therapies), leading to further challenges in identifying eligible patients. Logistical barriers to clinical trials may include the absence of an infrastructure for clinical trials; the absence of systematic, centralized databases; the potential lack of therapeutic equipoise; and the lack of resources to provide coordination of collaborative efforts at multiple study sites. Additional challenges of researchers include the ethical issues involved in performing research studies in children compared with adults, and the lack of suitable, clinically relevant, or so-called “hard,” end points in pediatric patients with neuromuscular disease.18
Clinical trials in DMD are increasing due to technical advances in genetics, muscle biology and muscle imaging, and translational science.19, 20, 21, 22, 23, 24 Challenges exist in recruiting, and these challenges continue to undermine the research. Given the growing importance of patient engagement in clinical and translational research,6, 25 we sought to identify knowledge and attitudes on engagement in clinical research studies among parents of boys with DMD, as well as researchers and clinicians involved in research in DMD. From qualitative investigation of family-centered and clinician-based attitudes and perceptions, the insight gained may improve the design of future DMD clinical research protocols and improve participation in future clinical trials.
Section snippets
Patients and Methods
In the present study, we targeted the recruitment efforts toward sites involved in the Cooperative International Neuromuscular Research Group, a clinical research academic consortium, and associated Muscular Dystrophy Association clinics. Five geographically and demographically diverse sites (Pittsburgh, Pennsylvania; Washington, DC; Houston, Texas; Minneapolis, Minnesota; and Sacramento, California) with varying levels of DMD research recruitment and participation were selected to maximize
Results
Totals of 28 parents and 33 clinicians completed the 13 focus-group sessions. Table I describes the demographic characteristics of the parents and the clinical characteristics of their sons with DMD. Table II describes the clinicians and their roles within DMD research.
Discussion
Through focus-group sessions with parents of boys with DMD and with clinicians involved in recruitment and research in DMD, our goal was to understand the barriers to engaging the DMD community in clinical trials, as well as strategies that build healthy partnerships and inform and assist with recruitment efforts.
Parents and clinicians provided innovative and thoughtful discussions regarding research participation and approaches to elicit family engagement in research in DMD. While there may
Conclusions
Effective recruitment for clinical studies in rare diseases requires a truly committed and engaged study team, as well as the necessary resources to overcome the multitude of barriers that families face. A clearly delineated recruitment plan, developed together with families, should be the standard operating procedure during clinical trial development. Protocols utilizing direct family-centered strategies to provide information and recruit research participants in studies in rare diseases are
Conflicts of Interest
This research and its publication were funded by the Foundation to Eradicate Duchenne (project 709537). The authors work and have personal experiences with DMD. The authors have indicated that they have no other conflicts of interest with regard to the content of this article.
Acknowledgments
The authors thank the Foundation to Eradicate Duchenne and all parents of boys with DMD and their sons, as well as clinicians involved in research in DMD, especially those parents and clinicians who gave of their time to participate in the focus-group sessions.
R.M. Bendixen conceived and developed the study protocol, served as the focus-group moderator, acquired the data, performed data analyses and interpretation with coauthors, drafted and edited the manuscript, and gave final approval for
References (39)
- et al.
Investigator beliefs and reported success in recruiting minority participants
Contemp Clin Trials
(2006) - et al.
Why rare diseases are an important medical and social issue
Lancet
(2008) - et al.
A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy
Clin Ther
(2014) - et al.
An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants
Contemp Clin Trials
(2009) - et al.
What the orphan drug act has done lately for children with rare diseases: a 10-year analysis
Pediatrics
(2012) - Vickers PJ. Challenges and opportunities in the treatment of rare diseases. Drug Discovery World, spring 2013....
- et al.
The TREAT-NMD Duchenne muscular dystrophy registries: conceptions, design and utilization by industry and academia
Human Mut
(2013) - et al.
Collaborating to bring new therapies to the patient—the TREAT-NMD model
Acta Myologica
(2009) - et al.
Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience
J Genet Counseling
(2014) - et al.
Clinical trials in rare disease: challenges and opportunities
J Child Neurol
(2013)